$35.85
0.55% yesterday
Nasdaq, Aug 21, 10:16 pm CET
ISIN
US8902604094
Symbol
TNXP

Tonix Pharmaceuticals Holding Corp. Stock price

$35.85
-9.25 20.51% 1M
+26.68 290.95% 6M
+2.87 8.70% YTD
-0.15 0.42% 1Y
-25,964.15 99.86% 3Y
-562,524.15 99.99% 5Y
-4,198,399,964.15 100.00% 10Y
-1,279,964.15 100.00% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
-0.20 0.55%
ISIN
US8902604094
Symbol
TNXP
Industry

Key metrics

Basic
Market capitalization
$316.0m
Enterprise Value
$190.7m
Net debt
positive
Cash
$125.3m
Shares outstanding
7.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
32.1 | 25.5
EV/Sales
19.4 | 15.4
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
85.7%
Return on Equity
-93.2%
ROCE
-50.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$9.8m | $12.4m
EBITDA
$-82.5m | -
EBIT
$-84.5m | $-108.2m
Net Income
$-81.4m | $-94.4m
Free Cash Flow
$-65.4m
Growth (TTM | estimate)
Revenue
-21.1% | 22.9%
EBITDA
8.6% | -
EBIT
11.3% | -39.2%
Net Income
45.4% | 27.4%
Free Cash Flow
13.5%
Margin (TTM | estimate)
Gross
29.3%
EBITDA
-839.1% | -
EBIT
-859.3%
Net
-828.2% | -761.4%
Free Cash Flow
-665.1%
More
EPS
$-11.1
FCF per Share
$-8.7
Short interest
16.4%
Employees
81
Rev per Employee
$120.0k
Show more

Is Tonix Pharmaceuticals Holding Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Tonix Pharmaceuticals Holding Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Tonix Pharmaceuticals Holding Corp. forecast:

Buy
88%
Hold
13%

Financial data from Tonix Pharmaceuticals Holding Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
9.83 9.83
21% 21%
100%
- Direct Costs 6.95 6.95
29% 29%
71%
2.88 2.88
7% 7%
29%
- Selling and Administrative Expenses 50 50
34% 34%
505%
- Research and Development Expense 36 36
41% 41%
363%
-82 -82
9% 9%
-839%
- Depreciation and Amortization 1.98 1.98
60% 60%
20%
EBIT (Operating Income) EBIT -84 -84
11% 11%
-859%
Net Profit -81 -81
45% 45%
-828%

In millions USD.

Don't miss a Thing! We will send you all news about Tonix Pharmaceuticals Holding Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tonix Pharmaceuticals Holding Corp. Stock News

Positive
Seeking Alpha
2 days ago
The Tonix Pharmaceuticals Holding Corp. stock price has pulled back so much, and they hold a clear campaign runway for Tonmya into 2026. Despite approval, TNXP shares dropped due to concerns over valuation, potential dilution, and uncertainty around commercialization and pricing. Tonmya's novel formulation and high unmet need could drive strong adoption, with revenue potential of $219M–$365M an...
Positive
Investors Business Daily
4 days ago
Tonmya is the first FDA-approved fibromyalgia drug in more than 15 years.
Positive
Seeking Alpha
6 days ago
Tonix's Tonmya received FDA approval, marking the first new fibromyalgia therapy in 15 years and driving a post-market stock surge. Despite the approval, I maintain a Hold rating due to Tonix's limited cash, ongoing losses, and likely need for dilutive fundraising. Tonmya's unique sublingual formulation and unmet market need are positives, but safety concerns and commercial execution risks remain.
More Tonix Pharmaceuticals Holding Corp. News

Company Profile

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Head office United States
CEO Seth Lederman
Employees 81
Founded 2007
Website www.tonixpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today